Vol 7, Supplement 2 (April 2018): Translational Lung Cancer Research


Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution
Massimiliano Salati, Cinzia Baldessari, Bruna Cerbelli, Andrea Botticelli
Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer
Jan Trøst Jørgensen, Karsten Bork Nielsen
Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option
Antonio Passaro, Filippo de Marinis
Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start
Francesco Facchinetti, Luc Friboulet
Stage III non-small cell lung cancer: escalation matters, but how?
Aparna Madhukeshwar Hegde, Paul Raymond Walker
A promising result of locoregional tumor control with biologically adaptive radiotherapy in patients with locally advanced non-smallcell lung cancer
Yukinori Matsuo
Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial
John K. Field, Stephen W. Duffy, David R. Baldwin
Repurposing established cyclic adenosine monophosphate reducing agents for the prevention and therapy of epidermal growth factor receptor inhibitor resistance in non-small cell lung cancer
Hildegard M. Schuller
Stressing the need to overcome EGFR tyrosine kinase inhibitor resistance
Leila Toulabi, Bríd M. Ryan
First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
Biagio Ricciuti, Rita Chiari
No room for statins in the quest for survival benefits in small cell lung cancer
Francesco Facchinetti, Marcello Tiseo
The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations
Lore Decoster, Philippe Giron, Sacha Mignon, Jacques De Grève
Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer
Jyoti Malhotra, Salma K. Jabbour
EGFR targeted therapy for lung cancer: are we almost there?
Giulio Metro
Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine
Hidehito Horinouch
Quality of life for non-small cell lung cancer patients in the age of immunotherapy
Robert A. Ramirez, Jonathan Lu, Katharine E. H. Thomas
Durvalumab for non-resectable stage IIIB non-small cell lung cancer—a small step or a big leap?
Wolfram C. M. Dempke, Klaus Fenchel
Editorial commentary: meeting a paramount challenge
Ping Yang
Can we use interleukin-1β blockade for lung cancer treatment?
Adrian Gottschlich, Stefan Endres, Sebastian Kobold
Osimertinib in untreated epidermal growth factor receptor (EGFR)- mutated advanced non-small cell lung cancer
Vanesa Gregorc, Chiara Lazzari, Niki Karachaliou, Rafael Rosell, Mariacarmela Santarpia
Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy
Mark R. Waddle, Stephen Ko, Margaret M. Johnson, Yanyan Lou, Robert C. Miller, Anna C. Harrell, Daniel M. Trifiletti
The continued EGFR-TKI with cytotoxic chemotherapy at progression—poison or medicine?
Shin-Kyo Yoon, Chang Min Choi, Jae Cheol Lee
Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?
Giannis Mountzios